In the last three months, 715 cases have been reported from
24 countries and areas. Over the past 4 weeks, 246
cases of mpox have been identified from 20 countries and
areas.

Since 7 March 2022, a total of 28 872 cases of mpox (formerly named
monkeypox) have been identified through IHR mechanisms, official public
sources and The European Surveillance System (TESSy) up to 14 January
2025, 14:00, from 47 countries and areas throughout the WHO European
Region. Case-based data were reported for 28 632
cases from 42 countries and areas to ECDC and the WHO Regional Office
for Europe through TESSy, up to 14 January 2025, 10:00. Of the 28 632
cases reported in TESSy, 28 446 were laboratory confirmed.

The majority of cases were male
(98%; n = 28 551) with the
most affected age group being 31–40 years-old
(39%; n = 28 588). Of the
12 872 male cases with known sexual behaviour, 97% were reported as men
who have sex with men. Among cases with known HIV status, 37%
(n = 12 149) were HIV-positive.
The majority of cases presented with a rash
(91%; n = 10 203). Systemic symptoms
such as fever, fatigue, muscle pain, chills, or headache were present in
53% of cases (n = 10 203).
There were 941 cases hospitalised (7%), of which
303 cases required clinical care. Nine cases were admitted to ICU, and 9
cases were reported to have died.

Since August 2024, 16 cases of clade 1b have been detected in
5 countries. All these cases either travelled themselves or are close
contacts of travelers from countries with known local transmission of
clade Ib.

An overview of the global situation can be found here: https://worldhealthorg.shinyapps.io/mpx_global/.